Sagimet Biosciences Inc.
SGMT
$5.14
-$0.07-1.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 40.94% | 11.70% | -27.94% | -174.19% | -98.76% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.86% | 91.95% | 40.02% | 62.13% | 12.39% |
| Change in Net Operating Assets | -217.23% | 111.67% | -108.46% | 1,571.82% | 1,407.86% |
| Cash from Operations | -7.34% | 47.98% | -61.54% | -134.15% | -55.64% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 45.77% | -87.98% | 82.32% | 13.77% | 150.20% |
| Cash from Investing | 45.77% | -87.98% | 82.32% | 13.77% | 150.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -- | -- | 103.70% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 315.08% | 48.11% | 72.30% | -110.94% | 95.60% |